Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401850 | 0.80 | HRH4 (0.46) | HRH4ALOX15KMT2AKDM4EMEN1 | |
| SCHEMBL14829239 | 0.72 | HRH4 (0.50) | HRH4ALOX15 | |
| SCHEMBL14828912 | 0.70 | HRH4 (0.49) | HRH4ALOX15 | |
| SCHEMBL462840 | 0.70 | HRH4 (0.64) | HRH4 | |
| SCHEMBL463013 | 0.69 | HRH4 (0.45) | HRH4KDM4E | |
| SCHEMBL14829054 | 0.68 | HRH4 (0.48) | HRH4ALOX15KDM4E | |
| SCHEMBL10386301 | 0.68 | HRH4 (0.61) | HRH4ALOX15KMT2AKDM4EMEN1 | |
| SCHEMBL14828911 | 0.66 | HRH4 (0.52) | HRH4 | |
| SCHEMBL14997086 | 0.66 | HRH4 (0.40) | HRH4ALOX15KMT2AMEN1 | |
| SCHEMBL14828758 | 0.65 | HRH4 (0.48) | HRH4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| CN-102869666-A | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC | 2013-01-09 | — | — | CN | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885ALOX15 1142/4885KMT2A 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.